Community Bank & Trust Waco Texas Has $584,000 Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Community Bank & Trust Waco Texas trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,526 shares of the medical equipment provider’s stock after selling 275 shares during the quarter. Community Bank & Trust Waco Texas’ holdings in Zimmer Biomet were worth $584,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Stonebridge Financial Group LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter worth about $25,000. Summit Trail Advisors LLC grew its position in shares of Zimmer Biomet by 31.8% during the 4th quarter. Summit Trail Advisors LLC now owns 4,533 shares of the medical equipment provider’s stock worth $480,000 after buying an additional 1,095 shares during the period. Paladin Wealth LLC grew its position in shares of Zimmer Biomet by 9.5% during the 4th quarter. Paladin Wealth LLC now owns 5,457 shares of the medical equipment provider’s stock worth $576,000 after buying an additional 472 shares during the period. Stephens Inc. AR grew its position in shares of Zimmer Biomet by 3.4% during the 4th quarter. Stephens Inc. AR now owns 6,116 shares of the medical equipment provider’s stock worth $646,000 after buying an additional 202 shares during the period. Finally, Howland Capital Management LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter worth about $261,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Trading Down 0.5 %

Shares of Zimmer Biomet stock opened at $100.40 on Tuesday. The company has a quick ratio of 0.70, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The stock has a market cap of $19.99 billion, a P/E ratio of 22.56, a P/E/G ratio of 1.83 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12-month low of $99.67 and a 12-month high of $133.90. The business’s 50 day moving average is $107.34 and its 200-day moving average is $108.07.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the firm posted $2.20 EPS. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s payout ratio is presently 21.57%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ZBH. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Truist Financial reiterated a “hold” rating and issued a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research report on Monday. Wells Fargo & Company boosted their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Royal Bank of Canada decreased their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday. Finally, Barclays cut their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.